ClinicalTrials.gg
CompletedNCT03477409ARMED NEOUpdated Nov 17, 2026

Exposure of NICU Patients to PVC Plasticizers in At-risk Clinical Situation: Biomonitoring Study From Urinary Samples

An observational study in Neonates or Premature Babies, Patient With Urinary Catheter and Patient Hospitalized in NICU, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Updated Nov 17, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
104
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Premature Birth with a site in France — 40 open to participants now, 46 under way, 2 of them phase 3. Premature Birth · France.

Enrollment
54th of 99
104 · median 130
Started
2018
with 18 others
Observational
99 of 205
21 open now
Registered
86th of 205
by date
Lead sponsor
7 of 205
University Hospital, Clermont-Ferrand

Among the 205 studies in Premature Birth with a site in France, this one is the 54th largest by enrollment of the 99 observational ones that give a count, is one of 19 that started in 2018, is one of 99 observational ones, and was the 86th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

40 of the 205 studies in Premature Birth with a site in France are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Premature Birth with a site in France, or all of them as a file.
02

Study summary

In response to restrictions related to the use of DEHP as a plasticizer for PVC medical devices (MDs), manufacturers have resorted to alternative plasticizers. These are now integrated into many MDs such as infusion sets, extension lines, extracorporeal circuits, nutrition tubings ... etc. The ARMED project (2012-2015) funded by the ANSM, whose goal was to prioritizing the risk linked to the migration of these plasticizers from MDs, has shown that TOTM and DEHT present the best benefit / risk ratio due to lower migration and cytotoxicity. Nevertheless, it is important to evaluate the level of exposure of neonatal intensive care patients, due to the multi exposure to MD made of PVC, the frequent use of intravenous route and the vulnerability of this at-risk population to the metabolites of these plasticizers.

Read the detailed description

The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites

03

Conditions studied

  • Neonates or Premature Babies
  • Patient With Urinary Catheter
  • Patient Hospitalized in NICU

Browse trials for

Keywords

  • plasticizers
  • medical devices
  • neonates
  • exposition
04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

minor patient in NICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • hospitalized minor patient in NICU
  • hospitalized patient in one of the planned services of the study- hospital stay provided for inclusion ≥ 48 hours
  • patient with a urinary catheter at the time of inclusion in the study
  • patient undergoing during the stay at least 1 of the following medical procedures: enteral nutrition, parenteral nutrition, extra-renal purification, ECMO, transfusion, lipid infusion, plasmapheresis
  • patient whose parents have expressed their non-opposition to his participation in the study

Exclusion criteria

Exclusion Criteria:

  • death of the patient
  • leaving hospital
  • patient becoming anuric (diuresis \<1mL / kg / h for more than 24 hours) under study
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
104 participants (actual)
Patient registry
No

Groups and cohorts

  • Neonatal intensive care patients

    The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites

    Other: plasticizers

Interventions

  • Otherplasticizers

    The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites

06

What researchers measure

Primary outcomes

  1. Measurement of urinary levels of DEHT metabolites

    The studied metabolites are specific biological markers

    Time frame: at day 1

  2. Measurement of urinary levels of TOTM metabolites

    The studied metabolites are specific biological markers

    Time frame: at day 1

Secondary outcomes

  1. Correlation of urinary levels of TOTM and DEHT metabolites to corresponding plasticizers doses released by PVC medical devices to which patients are exposed

    Quantities of plasticizers (TOTM and DEHT) are measured within each MD to which neonates are exposed in NICU. The release doses of plasticizers are evaluated with mathematical model (built from ex vivo experimentations). The study evaluates whether there is a correlation between the doses of TOTM and the DEHT released by the MD and the metabolites levels found in the urine of exposed patients

    Time frame: 18 months after the beginning of the study

  2. Comparison of urinary levels of TOTM and DEHT and their metabolites to in vitro cytotoxicity and endocrine disruption and to toxicological data from the literature.

    The Armed Neo project include laboratory studies to evaluate the cytotoxicity and endocrine disrupting effects of plasticizers and their metabolites. These studies show the concentrations above which DHT, TOTM and metabolites are toxic. The concentrations obtained in the urines of newborns will be compared to these toxicity threshold values

    Time frame: 18 months after the beginning of the study

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Bernard L, Bouattour Y, Masse M, Boeuf B, Decaudin B, Genay S, Lambert C, Moreau E, Pereira B, Pinguet J, Richard D, Sautou V, For The Armed Study Group. Association between Urinary Metabolites and the Exposure of Intensive Care Newborns to Plasticizers of Medical Devices Used for Their Care Management. Metabolites. 2021 Apr 19;11(4):252. doi: 10.3390/metabo11040252. PubMed 33921860 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2018 to primary completion in Nov 2018, 9 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jan 2019 → Nov 2018 and completion Jan 2019 → Apr 2019.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2018
First posted
Mar 26, 2018
StartActual
Feb 1, 2018
Primary completionActual
Nov 30, 2018was Jan 2019
CompletionActual
Apr 30, 2019was Jan 2019
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Primary completion
Jan 31, 2019→Nov 30, 2018 (actual)
Nov 17, 2026
Study completion
Jan 31, 2019→Apr 30, 2019 (actual)
Nov 17, 2026
Enrollment
90 (estimated)→104 (actual)
Nov 17, 2026
Publications
Results publication added: Bernard L, Bouattour Y, Masse M, Boeuf B, Decaudin B, Genay S, Lambert C, Moreau E, Pereira B, Pinguet J, Richard D, Sautou V, For The Armed Study Group. Assoc… PubMed 33921860 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Bernard L, Bouattour Y, Masse M, Boeuf B, Decaudin B, Genay S, Lambert C, Moreau E, Pereira B, Pinguet J, Richard D, Sautou V, For The Armed Study Group. Assoc… PubMed 33921860 ↗
    Primary completion Jan 31, 2019→Nov 30, 2018 (now actual)
    Study completion Jan 31, 2019→Apr 30, 2019 (now actual)
    Enrollment 90 (estimated)→104 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03477409
Responsible party
Sponsor
First posted
Mar 26, 2018
Start date
Feb 1, 2018
Primary completion
Nov 30, 2018
Completion
Apr 30, 2019
Last update
Nov 17, 2026

Study contacts

Valérie SAUTOU
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion